» Articles » PMID: 16512814

Prostaglandin E Potentiates the Immunologically Stimulated Histamine Release from Human Peripheral Blood-derived Mast Cells Through EP1/EP3 Receptors

Overview
Journal Allergy
Date 2006 Mar 4
PMID 16512814
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mast cells cultured from human peripheral blood have been widely used to study human mast cell function. Prostanoids are the important regulators of mast cell activity, however, there were no reports about the class of prostanoid receptors expressed on such cultured cells.

Aims: The present study was to characterize pharmacologically the prostanoid receptors by investigating the effects of prostanoid receptor agonists on the immunoglobulin E (IgE)-mediated histamine release from the cultured mast cells.

Methods: Mast cells cultured from human progenitor cells in peripheral blood were sensitized with human myeloma IgE, and then challenged with anti-human IgE following pretreatment with diverse prostanoid receptor agonists. The histamine content in supernatants and cell pellets were measured by histamine auto-analyzer.

Results: Of the prostanoid receptor agonists tested, the prostaglandin E2 (PGE2) receptor (EP receptor) agonist PGE2 (10(-7) to 10(-11) M) produced concentration-related potentiation of IgE-mediated histamine release from the cultured mast cells. Sulprostone, an EP1/EP3 agonist, SC-46275, a selective EP3 agonist, and 11-deoxy-PGE1, a selective EP2/EP3/EP4 agonist also caused a significant increase in histamine release induced by anti-IgE. BW245C, fluprostone, cicaprost and U46619 for the prostaglandin D2, F2alpha, I2, and thromboxane A2 receptors respectively, and the EP2/EP4 receptor agonist butaprost had little effect on anti-IgE stimulated histamine release from mast cells.

Conclusions: The present results suggest that PGE2 potentiates the IgE-mediated histamine release from the cultured mast cell via EP3 and/or EP1 receptors.

Citing Articles

Prostaglandins in the Inflamed Central Nervous System: Potential Therapeutic Targets.

Sheremeta C, Yarlagadda S, Smythe M, Noakes P Curr Drug Targets. 2024; 25(13):885-908.

PMID: 39177131 PMC: 11774313. DOI: 10.2174/0113894501323980240815113851.


Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension.

Zeng C, Liu J, Zheng X, Hu X, He Y Respir Res. 2023; 24(1):263.

PMID: 37915044 PMC: 10619262. DOI: 10.1186/s12931-023-02559-3.


Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors.

Francica B, Holtz A, Lopez J, Freund D, Chen A, Wang D Cancer Res Commun. 2023; 3(8):1486-1500.

PMID: 37559947 PMC: 10408683. DOI: 10.1158/2767-9764.CRC-23-0249.


Advances in Understanding the Genetic Mechanisms of Zebrafish Renal Multiciliated Cell Development.

Wesselman H, Nguyen T, Chambers J, Drummond B, Wingert R J Dev Biol. 2023; 11(1).

PMID: 36648903 PMC: 9844391. DOI: 10.3390/jdb11010001.


Angioedema and Fatty Acids.

Wada A, Sawada Y, Sugino H, Nakamura M Int J Mol Sci. 2021; 22(16).

PMID: 34445711 PMC: 8396478. DOI: 10.3390/ijms22169000.